Share

April 05, 2016; 86 (16 Supplement) April 20, 2016

Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)

Anthony Traboulsee, Douglas Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Gaelle Klingelschmitt, Donna Masterman, Paulo Fontoura, Peter Chin, Hideki Garren, Stephen Hauser
First published April 4, 2016,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 86 no. 16 Supplement PL02.004
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 4, 2016.
Copyright & Usage: 
Copyright © 2016 by AAN Enterprises, Inc.

Author Disclosures

    1. Anthony Traboulsee14,
    2. Douglas Arnold12,8,
    3. Amit Bar-Or10,
    4. Giancarlo Comi15,
    5. Hans-Peter Hartung6,
    6. Ludwig Kappos11,
    7. Fred Lublin7,
    8. Krzysztof Selmaj9,
    9. Gaelle Klingelschmitt2,
    10. Donna Masterman5,
    11. Paulo Fontoura1,
    12. Peter Chin4,
    13. Hideki Garren3 and
    14. Stephen Hauser13
  1. Anthony Traboulsee14,
  2. Douglas Arnold12,8,
  3. Amit Bar-Or10,
  4. Giancarlo Comi15,
  5. Hans-Peter Hartung6,
  6. Ludwig Kappos11,
  7. Fred Lublin7,
  8. Krzysztof Selmaj9,
  9. Gaelle Klingelschmitt2,
  10. Donna Masterman5,
  11. Paulo Fontoura1,
  12. Peter Chin4,
  13. Hideki Garren3 and
  14. Stephen Hauser13
  1. 1F. Hoffmann La-Roche Ltd. Basel Switzerland
  2. 2F. Hoffmann La-Roche Ltd., Basel Switzerland
  3. 3F. Hoffmann-La Roche Ltd. Basel Switzerland
  4. 4Genentech South San Francisco CA United States
  5. 5Genentech, Inc. South San Francisco CA United States
  6. 6Heinrich Heine University Duesseldorf Düsseldorf Germany
  7. 7Icahn School of Medicine At Mount Sinai New York NY United States
  8. 8McGill University Montreal QC Canada
  9. 9Medical University of Lodz Lodz Poland
  10. 10Montreal Neurological Institute Montreal QC Canada
  11. 11Neurology and Department of Biomedicine, University Hospital Basel Switzerland
  12. 12NeuroRx Research Montreal QC Canada
  13. 13Univ of Calif San Francisco, Dept of Neurology San Francisco CA United States
  14. 14University of British Columbia Vancouver BC Canada
  15. 15University Vita-Salute Milan Italy

Article usage

Article usage: April 2016 to December 2022

AbstractFullPdfSource
Apr 20167900Highwire
May 201616800Highwire
Jun 20168700Highwire
Jul 20165700Highwire
Aug 20168700Highwire
Sep 20169900Highwire
Oct 201611700Highwire
Nov 20169300Highwire
Dec 20165500Highwire
Jan 20174600Highwire
Feb 20176500Highwire
Mar 20178600Highwire
Apr 20178900Highwire
May 20175000Highwire
Jun 20173300Highwire
Jul 201727500Highwire
Aug 20172600Highwire
Sep 20175600Highwire
Oct 20174300Highwire
Nov 20173000Highwire
Dec 20172900Highwire
Jan 20184000Highwire
Feb 20184500Highwire
Mar 20182300Highwire
Apr 20184900Highwire
May 20184300Highwire
Jun 20182600Highwire
Jul 20181200Highwire
Aug 20181700Highwire
Sep 20182100Highwire
Oct 20182000Highwire
Nov 20182400Highwire
Dec 20182800Highwire
Jan 20192900Highwire
Feb 20191900Highwire
Mar 20194200Highwire
Apr 20192800Highwire
May 20192200Highwire
Jun 20192200Highwire
Jul 20193800Highwire
Aug 20193800Highwire
Sep 20192500Highwire
Oct 20191300Highwire
Nov 20191600Highwire
Dec 20191300Highwire
Jan 20201200Highwire
Feb 20201400Highwire
Mar 20201700Highwire
Apr 20203100Highwire
May 20202500Highwire
Jun 20201800Highwire
Jul 2020800Highwire
Aug 20201300Highwire
Sep 20202000Highwire
Oct 20202400Highwire
Nov 20201600Highwire
Dec 20202000Highwire
Jan 20211700Highwire
Feb 20211700Highwire
Mar 20212200Highwire
Apr 20215000Highwire
May 20217300Highwire
Jun 20214800Highwire
Jul 20213300Highwire
Aug 20212200Highwire
Sep 20212400Highwire
Oct 20212700Highwire
Nov 20213200Highwire
Dec 20214700Highwire
Jan 20221500Highwire
Feb 20222300Highwire
Mar 20221900Highwire
Apr 20221800Highwire
May 20222400Highwire
Jun 20221200Highwire
Jul 20221500Highwire
Aug 20221000Highwire
Sep 20221900Highwire
Oct 20221700Highwire
Nov 20221100Highwire
Dec 20222800Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me